Dr. Al Kim, St. Louis, discusses the effects of obesity on lupus activity, organ damage, complement levels and mTor activation.
Dr. John Cush RheumNow
2 weeks 3 days ago
ACP Clinical Guideline on Treatments of Overweight or Obese Adults
In July 2026, ACP published its first living clinical guideline addressing pharmacologic management of overweight and obesity in nonpregnant adults in outpatient settings. As this therapeutic area is rapidly https://t.co/5oQIY7J2Aw
Dr. John Cush RheumNow
2 weeks 3 days ago
Obesity Journal Club https://t.co/CxAWoGBqpx
Dr. John Cush RheumNow
2 weeks 3 days ago
Music and Pain Relief
A new scoping review in Pain Reports by Bradt et al., examines the effect of MBIs on pain management. While its efficacy is well established, how or why music relieves pain has never been fully explained. This systematic review is based on 663 records and https://t.co/HBCURxB9WC
Dr. John Cush RheumNow
2 weeks 3 days ago
EBR Journal Club: Dapirolizumab Pegol in SLE (PHOENYCS GO)
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. Each review covers four domains: Does this apply to my patients? What is the risk https://t.co/1jAvPfRI0m
Dr. John Cush RheumNow
2 weeks 3 days ago
Join us for the first of four webinars this month!
This Journal Club will explore the TOGETHER PsA and STEP 9 trials, and what emerging evidence tells us about the complex relationship between obesity, weight loss and rheumatic disease.
The authors and leading experts will:
• https://t.co/xpnqim1VKH
We all know that osteoarthritis is the most common form of arthritis in the world, and that obesity is its most modifiable risk factor. What I really want to focus on is the role that GLP-! receptor agonists might be playing in our management of osteoarthritis. So why does this matter?
Recently JAMA updated its guidance on artificial intelligence (AI) in medical publications. Now, the ACP has published a position paper regarding the use and ethical considerations for the use of AI in medical practice.
Dr. John Cush RheumNow
2 weeks 3 days ago
12 mos Danish study of 157 822 first-time semaglutide for obesity management (SOM) intiators. 77 483 discontinued treatment w/in 12 mos. (13% at 3 mo, 27% 6 mos, 39% @ 9 mos. D/C more likely in younger, men, low-income, on GI or psych meds, & pts with comorbididities. Few https://t.co/oJLnrxXFz0
Dr. John Cush RheumNow
2 weeks 3 days ago
Swedish Pt Registry of 4317 AAV pts showed GPA & MPA had signif incr risk of CV dz (HR 2.04) & thromboembolism (HR 2.45); males incr MI risk (HR 2.25) & females incr ischemic stroke risk (HR 1.64). Sibs had no excess CVD-TE risk. The highest CVD-TE risk occurred within 3 mos. of https://t.co/FdbIXoCZf0
Dr. John Cush RheumNow
2 weeks 4 days ago
Join us for the first of four webinars this month!
Our Journal Club explores the TOGETHER PsA and STEP 9 trials, and what emerging evidence reveals about obesity, weight loss and rheumatic disease.
Featuring Drs. Philip Mease, Tom Appleton and Jack Cush. https://t.co/KkVJPyhKF1
